In 2017 the results of the COMBI-MB, a phase 2 clinical trial designed to assess the safety and efficacy of Dabrafenib combined with Trametinib in patients with BRAF V600 mutated melanoma with brain metastases, were published. The gene discussed is BRAF; the disease is melanoma.